Off Label NCCN denied as not medically necessary by Aetna?

Aetna's specific coverage criteria for off label nccn are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied an Off-Label NCCN-Supported Treatment as Not Medically Necessary — and How to Appeal

A medical-necessity denial from Aetna means Aetna's reviewers concluded that the requested treatment did not meet the plan's clinical coverage criteria as applied to your specific case. For off-label drug use supported by NCCN guidelines, this type of denial often reflects a gap between what your physician submitted in the prior authorization request and what Aetna's Clinical Policy Bulletin requires to be documented — rather than a genuine clinical disagreement about whether the treatment is appropriate for you.

### Why This Denial Is Appealable

Medical-necessity determinations must be based on sound clinical evidence and applied consistently with Aetna's own published criteria. When the treatment is listed in the NCCN Compendium for your diagnosis and stage, an argument that it is not medically necessary is difficult to sustain on external review. ACA §2719 and ERISA §503 entitle you to a full internal appeal and then an independent external review if the internal appeal fails. IROs reviewing oncology medical-necessity denials look closely at whether the insurer applied its own criteria correctly.

### Federal Appeal Framework

• Internal appeal: You have 180 days from the denial to file. Aetna must decide urgent appeals within 72 hours and standard appeals within 30–60 days.
• External review: Available after a final internal denial. File within approximately four months of that decision. The IRO's ruling is binding.
• Expedited option: If your health is at serious risk from delay, request both expedited internal and expedited external review simultaneously in writing.

### Documentation to Gather

1. Diagnosis, staging, and biomarker records — complete pathology reports, molecular testing results, and imaging that establish exactly what Aetna's policy requires to confirm the eligible diagnosis. 2. Prior treatment history — dated records showing every prior therapy, duration, and documented clinical outcome or reason for discontinuation. 3. Clinical severity documentation — performance-status scores, functional assessments, or other objective severity measures recorded in your chart by the treating physician. 4. NCCN guideline or Compendium support — the specific category and indication under which this drug and your diagnosis appear, with the current edition date. 5. Prescriber medical-necessity letter — a detailed letter from your oncologist or specialist that walks through each of Aetna's published criteria and maps your specific chart facts to each one.

### Criteria-Mapping Structure

Obtain Aetna's Clinical Policy Bulletin for this drug or drug class and build a side-by-side table:

| Aetna Medical-Necessity Criterion | Specific Chart Evidence Meeting It | |---|---| | Confirmed diagnosis and histology | [Pathology report date and findings] | | Stage or extent of disease | [Staging workup, date] | | Prior therapy requirements met | [Drug, dates, documented outcome] | | NCCN Compendium support | [NCCN category, indication, edition] | | Prescriber specialty and documentation | [Prescribing physician credentials and letter] |

Every row should be answered with a specific document and page or note date. Unanswered rows are the primary reason medical-necessity appeals fail — make sure none are left blank.